USO 18283
A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)
Disease Types: Genitourinary Cancer Research
Eligibility Requirements:
-locally advanced or metastatic urothelial cancer with measurable disease
-No: immunodeficiency disease; prior anti-cancer with mono-clonal antibodies within last 4 weeks; prior treatment with irinotecan; known active CNS metastasis or carcinomatous meningitis; active serious cardiac disease (MI or unstable angina within last 6 months, serious ventricular arrhythmia, congestive heart failure class 3 or 4, ejection failure less than 40%); chronic ulcerative colitis, Crohn’s disease, or history of bowel obstruction; prior history of significant bleeding, intestinal obstruction, or GI perforation within last 6 months; known HIV, Hep B or Hep C
Available at: